

PUBLICATIONS

1. **O'Rourke, M.** and Stevens, E. (1993) Genetic structure of *Neisseria gonorrhoeae* populations: a non-clonal pathogen. *Journal of General Microbiology* **139**: 2603 - 2611.
2. Maynard Smith, J., Smith, N.H., **O'Rourke, M.** and Spratt, B.G. (1993). How clonal are bacteria? *Proc. Natl. Acad. Sci. USA.* 90: 4384 - 4388.
3. Vazquez, J.A., De la Fuente, L., Berron, S., **O'Rourke, M.**, Smith, N.H., Zhou, J. and Spratt, B.G. (1993). Ecological separation and genetic isolation of *Neisseria gonorrhoeae* and *Neisseria meningitidis*. *Current Biology* 3: 567 - 572.
4. **O'Rourke, M.** and Spratt, B.G. (1994). Further evidence for the non-clonal population structure of *Neisseria gonorrhoeae*: extensive genetic diversity within isolates of the same electrophoretic type. *Microbiology* 140: 1285 - 1290.
5. Spratt, B.G., Carpenter, G., Feil, E., **O'Rourke, M.**, Smith, N.H. and Zhou, J. (1994). The population biology of the pathogenic *Neisseria*. pp 305 - 307. In *Neisseria 94*, eds Evans, J.S., Yost, S.E., Maiden, M.C.J. and Feavers, I.M.
6. Vazquez, J.A., Berron, S., **O'Rourke, M.**, Carpenter, G., Feil, E., Smith, N.H. and Spratt, B.G. (1995). Interspecies recombination in nature: a meningococcus that has acquired a gonococcal PIB porin. *Molecular Microbiology* 15: 1001 - 1007.
7. **O'Rourke, M.**, Ison, C.A., Renton, A. M. and Spratt, B.G. (1995). Opa-typing- a high resolution tool for studying the epidemiology of gonorrhoea. *Molecular Microbiology* 17: 865 - 875.
8. Spratt, B.G., Smith, N.H., Zhou, J., **O'Rourke, M.** and Feil, E. (1995). The population genetics of the pathogenic *Neisseria*. pp 143 - 160. In *The Population Genetics of Bacteria*, eds. Baumberg, S., Young, J.P.W., Wellington, E.M.H., and Saunders, J.R. SGM symposium No. 52. (Cambridge University Press, Cambridge, UK.).
9. Gutjahr, T.S., **O'Rourke, M.** and Spratt, B.G. (1997). Arginine, Hypoxanthine and Uracil requiring (AHU-) isolates of *Neisseria gonorrhoeae*: Evidence for the existence of a clone in a non-clonal population. *Microbiology* 143: 633 - 640.
10. van Alphen, L., Duim, B., Caugant, D.A., **O'Rourke, M.** and Bowler, L.D. (1997). Differences in genetic diversity of nonencapsulated *Haemophilus influenzae* from various diseases. *Microbiology* 143: 1423 - 1431.
11. Livey I, **O'Rourke, M.**, Traweger A, Savidis-Dacho H, Crowe BA, Barrett PN, Yang X, Dunn JJ, Luft BJ. A new approach to a Lyme disease vaccine. *Clin Infect Dis.* 2011 Feb; 52 Suppl 3:s266-70.
12. **O'Rourke, M.**, Traweger, A., Lusa, L., Stupica, D., Maraspin, V., Barrett, P.N, Strle, F., and Livey, I. Quantitative detection of *Borrelia burgdorferi sensu lato* in erythema migrans skin lesions using

- internally controlled duplex real time PCR. *PLoS One*. 2013 May 16;8(5):e63968. doi: 10.1371/journal.pone.0063968
13. Schwendinger M.G., **O'Rourke, M.**, Traweger A., Savidis-Dacho H., Pilz A., Portsmouth D., Livey I., Barrett P.N., Crowe B.A. Evaluation of OspA Vaccination-Induced Serological Correlates of Protection against Lyme Borreliosis in a Mouse Model. *PLoS One*. 2013 Nov 18;8(11):e79022. doi: 10.1371/journal.pone.0079022.
 14. Wressnigg N, van der Velden MV, Portsmouth D, Draxler W, **O'Rourke M**, Richmond P, Hall S, McBride WJ, Redfern A, Aaskov J, Barrett PN, Aichinger G. An inactivated Ross River Virus vaccine is well-tolerated and immunogenic in an adult population: a randomized phase 3 trial. *Clin Vaccine Immunol*. 2014 Dec 24. pii: CVI.00546-14. [Epub ahead of print].
 15. Wressnigg N, Barrett PN, Pöllabauer EM, **O'Rourke M**, Portsmouth D, Schwendinger MG, Crowe BA, Livey I, Dvorak T, Schmitt B, Zeitlinger M, Kollaritsch H, Esen M, Kreamsner PG, Jelinek T, Aschoff R, Weisser R, Naudts IF, Aichinger G. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with *Borrelia burgdorferi sensu lato* (2014). *Clin Vaccine Immunol*. 2014 Nov;21(11):1490-9. doi: 10.1128/CVI.00406-14. Epub 2014 Sep 3.
 16. Correlation of Culture Positivity, PCR Positivity, and Burden of *Borrelia burgdorferi sensu lato* in Skin Samples of Erythema Migrans Patients with Clinical Findings. Stupica D, Lusa L, Maraspin V, Bogovič P, Vidmar D, **O'Rourke M**, Traweger A, Livey I, Strle F. *PLoS One*. 2015 Sep 9;10(9):e0136600. doi: 10.1371/journal.pone.0136600. eCollection 2015.
 17. An open-label uncontrolled, multicenter study for the evaluation of the efficacy and safety of the dermal filler Princess VOLUME in the treatment of nasolabial folds. Kopera D, Palatin M, Bartsch R, Bartsch K, **O'Rourke M**, Höller S, Baumgartner RR, Prinz M. *Biomed Res Int*. 2015;2015:195328. doi: 10.1155/2015/195328. Epub 2015 Mar 3.
 18. Crowe B.A., **O'Rourke M.**, Schwendinger M.G., Traweger A., Savidis-Dacho H., Portsmouth D., Barrett P.N., Livey, I. Epidemiology and formulation studies demonstrating the immunogenicity and broad cross-strain protective efficacy of a novel multivalent recombinant Outer Surface Protein A Lyme Disease vaccine for Europe and North America. Submitted to *Infection and Immunity*, accepted, pending revision.
 19. Kopera D, Palatin M, Bartsch R, Bartsch K, O'Rourke M, Höller S, Baumgartner RR, Prinz M. An open-label uncontrolled, multicenter study for the evaluation of the efficacy and safety of the dermal filler Princess VOLUME in the treatment of nasolabial folds. *Biomed Res Int*. 2015;2015:195328. doi: 10.1155/2015/195328. Epub 2015 Mar 3.
 20. Schmidl D, Werkmeister R, Kaya S, Unterhuber A, Witkowska KJ, Baumgartner R, Höller S, **O'Rourke M**, Peterson W, Wolter A, Prinz M, Schmetterer L, Garhöfer G. A controlled, randomized, double blind study to evaluate the safety and efficacy of Chitosan-N-acetylcysteine for the treatment of Dry Eye Syndrome. *J Ocul Pharmacol Ther*. 2017 Jun;33(5):375-382. doi: 10.1089/jop.2016.0123. Epub 2017 Apr 25.

INTELLECTUAL PROPERTY /PATENTS

Four non-provisional patent applications were filed on May 13, 2011 entitled "Chimeric *ospA* genes, proteins and methods of use thereof." Each application (listed below) was filed in the U.S. Patent Office and internationally with the U.S. receiving office of the PCT.

- | | |
|---|-----------------|
| 1. 6745WO1 BX2011T00615 / 31315/44557A1 PCT | PCT/US11/36525 |
| 2. 6745U1US BX2011T00613 / 31315/44557A1 | USSN 13/107,787 |
| 3. 6745WO2 BX2011T00616 / 31315/44557A2 PCT | PCT/US11/36533 |
| 4. 6745U2US BX2011T00614 / 31315/44557A2 | USSN 13/107,796 |

Intellectual Property, constructs & platform technology for other vaccine projects investigated were sold to US Company BioVeris, details outlined in the following link:

<http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=28970§ionid=14>